A Pituitary Society update to acromegaly management guidelines

Guidelines and consensus statements ensure that physicians managing acromegaly patients have access to current information on evidence-based treatments to optimize outcomes. Given significant novel recent advances in understanding acromegaly natural history and individualized therapies, the Pituitary Society invited acromegaly experts to critically review the current literature in the context of Endocrine Society guidelines and Acromegaly Consensus Group statements. This update focuses on how recent key advances affect treatment decision-making and outcomes, and also highlights the likely role of recently FDA-approved therapies as well as novel combination therapies within the treatment armamentarium.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:24

Enthalten in:

Pituitary - 24(2021), 1 vom: 20. Feb., Seite 1-13

Sprache:

Englisch

Beteiligte Personen:

Fleseriu, Maria [VerfasserIn]
Biller, Beverly M K [VerfasserIn]
Freda, Pamela U [VerfasserIn]
Gadelha, Monica R [VerfasserIn]
Giustina, Andrea [VerfasserIn]
Katznelson, Laurence [VerfasserIn]
Molitch, Mark E [VerfasserIn]
Samson, Susan L [VerfasserIn]
Strasburger, Christian J [VerfasserIn]
van der Lely, A J [VerfasserIn]
Melmed, Shlomo [VerfasserIn]

Links:

Volltext

Themen:

12629-01-5
67763-96-6
Acromegaly
Growth hormone
Human Growth Hormone
Insulin-Like Growth Factor I
Insulin-like growth factor I
Journal Article
N824AOU5XV
Octreotide
Oral octreotide
Pegvisomant
Pituitary adenoma
RWM8CCW8GP
Receptors, Somatostatin
Review
Somatostatin receptor ligand

Anmerkungen:

Date Completed 01.11.2021

Date Revised 01.11.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1007/s11102-020-01091-7

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM316486043